On April 24, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported a €14,999,998.59 capital increase subscribed by Sanofi (Press release, Innate Pharma, APR 24, 2025, View Source [SID1234652125]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 of issue premium).
The subscription price of €1.7974 per share (€0.05 in nominal amount and €1.7474 of issue premium) is equal to the daily volume-weighted average price of the ordinary shares of Innate on the regulated market of Euronext in Paris on April 23, 2025.
"We welcome Sanofi’s strategic investment in Innate, which further reinforces the strength of our collaboration. The proceeds from this capital increase will be used for general corporate purposes, including extending our cash runway to support continued pipeline execution and long-term value creation", said Jonathan Dickinson, Chief Executive Officer of Innate Pharma.
This capital increase is to be completed pursuant to the 22nd resolution of the combined general meeting of shareholders of Innate held on 23 May 2024.
Closing of the capital increase is expected to take place on April 25, 2025. The newly issued shares will be admitted to trading on the regulated market of Euronext in Paris on the same day.
The tables below set out the Company’s shareholding, based on the information available to Innate as of the date of this press release, before and after the closing of the capital increase:
Before closing
Shareholder
Nb of Shares*
%
Nb of voting rights†
%
Novo Nordisk A/S
9,817,546
11.71%
9,817,546
11.60%
Medimmune Limited
7,485,500
8.93%
7,485,500
8.85%
Bpifrance Participations
6,389,406
7.62%
6,389,406
7.55%
Members of the Executive Board, Supervisory Board and Leadership Team
846,944
1.01%
911,444
1.08%
Treasury shares
18,575
0.02%
0
0%
Public
59,286,440
70.71%
59,995,085
70.92%
Total
83,844,411
100%
84,598,981
100%
After closing
Shareholder
Nb of Shares*
%
Nb of voting rights†
%
Novo Nordisk A/S
9,817,546
10.65%
9,817,546
10.56%
Sanofi-Aventis Participations
8,345,387
9.05%
8,345,387
8.98%
Medimmune Limited
7,485,500
8.12%
7,485,500
8.05%
Bpifrance Participations
6,389,406
6.93%
6,389,406
6.87%
Members of the Executive Board, Supervisory Board and Leadership Team
846,944
0.92%
911,444
0.98%
Treasury shares
18,575
0.02%
0
0%
Public
59,286,440
64.31%
59,995,085
64.55%
Total
92,189,798
100%
92,944,368
100%